Maximo Healthcare's trading volume on February 23rd was $398 million, a 52.34% decrease compared to the previous trading day.

On February 23, 2026, medical device company Masimo (MASI) had a trading volume of $398 million, ranking 311th among U.S. stocks that day. The trading volume decreased by 52.34% compared to the previous day, with a daily trading volume of 2.268 million shares.

Masimo (MASI) rose 0.09% on February 23, 2026, closing at $175.25. The stock increased by 34.65% over the past 5 trading days, 27.61% for the entire month of February, 34.75% year-to-date, and 3.11% over the past 52 weeks.

If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to listings less than 1 month or fewer than 5 trading days).

Masimo released its Q3 2025 fiscal year report on November 4, 2025. From December 29, 2024, to September 27, 2025, revenue was $1.114 billion, an increase of 8.53% year-over-year. Net loss was $220 million, turning from profit to loss compared to the previous year.

Masimo Corporation was founded in California in May 1989 and re-registered in Delaware in May 1996. The company is a global medical technology firm that develops, manufactures, and sells non-invasive patient monitoring products. Its mission is to improve patient outcomes and reduce healthcare costs by bringing non-invasive monitoring to new sites and applications. The company invented Masimo Signal Extraction Technology (SET), which provides the ability to measure motion and low-perfusion pulse oximetry, addressing the main limitations of traditional pulse oximeters. Pulse oximeters are non-invasive devices that measure arterial oxygen saturation levels, or the amount of oxygen delivered to tissues, and pulse rate. They are among the most common measurements performed in hospitals and outside. Masimo SET has been validated in over 100 independent clinical studies and is the only known pulse oximetry technology that has been shown to help clinicians detect critical congenital heart disease in newborns, reduce retinopathy of prematurity in preterm infants, and decrease rapid response activations in intensive care units and general floors. The company’s products include a monitor or circuit board for its proprietary single-patient use and reusable sensors and cables. The company sells its products directly to end users through its sales team and certain distributors, and also supplies some products to OEM partners for integration into their devices.